Spain-based medical diagnostics technology developer Stat-Diagnostica has completed a €25m ($28.5m) series C round featuring Boehringer Ingelheim Venture Fund, pharmaceutical company Boehringer Ingelheim’s corporate venturing unit.
Venture capital firm Gilde Healthcare led the round, which included Caixa Capital Risc, the venture capital arm of financial services firm La Caixa, and Spanish state-owned fund manager Axis, as well as Kurma Partners, Ysios Capital and Idinvest Partners.
Founded in 2010, Stat-Diagnostica has built an in-vitro diagnostic system called DiagCore that combines molecular and immunoassay techniques in one device. It will use the funds to prepare for DigiCore’s commercial release, which is planned for 2017.
Jordi Carrera, Stat-Diagnostica’s co-founder and chief executive, said: “This transaction paves the way for us to become the leader in the decentralised syndromic-approach diagnostics space, the fastest growing segment of in-vitro diagnostics.”
The company previously received €2m from Ysios and Axis in 2011 before securing $22.1m from Boehringer Ingelheim Venture Fund, Kurma, Caixa Capital Risc, Idinvest, Ysios and Axis two years later.